Lymphatica Medtech is a clinical-stage company based in Lausanne developing LymphoDrain, an implantable device intended to locally and actively replace lymphatic vessel drainage function for patients with lymphedema. LymphoDrain is designed for subcutaneous implantation via a minimally invasive technique and has shown promising results in a pilot feasibility study. The company recently opened a subsidiary in Italy to expand R&D and to manage manufacturing and clinical operations. Lymphatica says the new funding will accelerate clinical development and validation of the device. Leadership and board additions including Dan Rose as Chairman are intended to support clinical and commercial progress. The company positions itself to advance toward broader clinical validation and eventual patient access. Lymphatica developed LymphoDRAIN, an implantable device designed to treat chronic lymphedema and reduce patients' need for manual drainage therapy and compression garments. The company is a spinoff from EPFL and the Lausanne University Hospital (CHUV). It has received a seven-digit investment that will fund the start of clinical development and validation of the device. The round was led by High-Tech Gründerfonds with participation from business angels, the EIT Health and existing investors including LIVEventures. Through the EIT Health Start-up Rescue Instrument the company will also work to improve device connectivity via mobile apps. The company has appointed Laurent Duhoux (ex‑VP New Technology at Edwards Lifesciences) to its board and is led by CEO and co‑founder Marco Pisano. Lymphatica is a CHUV and EPFL spin-off developing LymphoDrain, an implantable micropump placed under the skin to remove fluid from affected limbs. The device is intended to slow or reverse the progression of lymphedema and help patients regain a normal lifestyle. The company is targeting a multi-billion dollar market. Its product is currently in the prototype and technical development phase. Lymphatica will use the awarded funds to prepare its first-in-man clinical trial, a crucial milestone on its roadmap.

Total raised

$0M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Jan 2019